Ken Griffin 10x Genomics, Inc. Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in 10x Genomics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 65,800 shares of TXG stock, worth $1.05 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65,800
Previous 147,000
55.24%
Holding current value
$1.05 Million
Previous $1.7 Million
54.82%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding TXG
# of Institutions
353Shares Held
118MCall Options Held
266KPut Options Held
191K-
Vanguard Group Inc Valley Forge, PA13.3MShares$211 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11.9MShares$189 Million0.98% of portfolio
-
Black Rock Inc. New York, NY6.39MShares$102 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.44MShares$86.4 Million0.03% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.5.38MShares$85.5 Million0.04% of portfolio
About 10x Genomics, Inc.
- Ticker TXG
- Exchange NASDAQ
- Sector Healthcare
- Industry Health Information Services
- Shares Outstandng 95,046,400
- Market Cap $1.51B
- Description
- 10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumabl...